35 results
6-K
EX-99.1
ACIU
AC Immune SA
24 May 23
Invitation to the Annual General Meeting 2023 To the Shareholders of AC Immune SA
4:07pm
receive or request these materials through their broker or bank and should be able to vote on the broker/bank portal. Voting Shareholders may vote
6-K
EX-99.1
ACIU
AC Immune SA
25 May 22
Notice of the Annual General Meeting 2022 To the Shareholders of AC Immune SA
4:29pm
Computershare. Shareholders who hold their shares through their broker or bank (“Beneficial Owners”), should receive these materials through their broker
6-K
EX-99.3
ACIU
AC Immune SA
22 Mar 22
AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update
7:03am
for product candidates that have not received regulatory approval, clinical trial materials and other research and development materials;
fees and expenses
6-K
EX-99.2
ACIU
AC Immune SA
22 Mar 22
AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update
7:03am
ingredients for product candidates that have not received regulatory approval, clinical trial materials and other research and development materials … of materials for use in the regulatory submission of the protocol and in the Phase 1 study. For the completed Phase 1, AC Immune was responsible for leading
6-K
EX-99.1
8zol iyy7
16 Mar 22
AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference
7:51am
6-K
EX-99.1
4lie0
7 Oct 21
Notice of the Extraordinary General Meeting (EGM) of 29 October 2021 To the Shareholders of AC Immune SA 1
7:27am
6-K
EX-10.1
z4tib33ow4oe73
4 Aug 21
Current report (foreign)
7:21am
6-K
EX-99.1
1hlu10obuy3jfqhcgxqh
21 May 21
Notice of the Annual General Meeting 2021 To the Shareholders of AC Immune SA 1
8:55am
424B5
mrhntb97rz 9ba0o6j
5 May 21
Prospectus supplement for primary offering
4:47pm
6-K
EX-99.1
7bm98u0g6rvlva0sn7f
28 Apr 21
Current report (foreign)
7:11am
6-K
8dmxju7ou
23 Mar 21
AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook
9:06am
6-K
EX-99.3
rbyrqsh91ked7m9o
23 Mar 21
AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook
9:06am
6-K
EX-99.2
nod0 6l09l
23 Mar 21
AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook
9:06am
6-K
EX-99.1
vtafk 2skp980pxx7gc5
13 Nov 20
Current report (foreign)
8:03am
6-K
EX-99.1
on8htz rxe9
5 Aug 20
Current report (foreign)
7:29am
6-K
EX-99.1
m71d5fa 0x5zhub
4 May 20
Current report (foreign)
8:32am
6-K
EX-99.2
4dvngh
30 Mar 20
AC Immune Reports Full-Year 2019 Financial Results and Provides 2020 R&D Outlook
9:08am